CytoMed Therapeutics (GDTC) Debt Ratio (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Debt Ratio for 5 consecutive years, with 0.05 as the latest value for Q4 2025.

  • Quarterly Debt Ratio rose 19.53% to 0.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.05 through Dec 2025, up 19.53% year-over-year, with the annual reading at 0.05 for FY2025, 17.64% up from the prior year.
  • Debt Ratio hit 0.05 in Q4 2025 for CytoMed Therapeutics, up from 0.04 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.15 in Q4 2022 to a low of 0.04 in Q4 2023.
  • Historically, Debt Ratio has averaged 0.09 across 5 years, with a median of 0.05 in 2025.
  • Biggest five-year swings in Debt Ratio: crashed 76.77% in 2023 and later rose 20.15% in 2024.
  • Year by year, Debt Ratio stood at 0.15 in 2021, then increased by 1.12% to 0.15 in 2022, then plummeted by 76.77% to 0.04 in 2023, then increased by 20.15% to 0.04 in 2024, then increased by 19.53% to 0.05 in 2025.
  • Business Quant data shows Debt Ratio for GDTC at 0.05 in Q4 2025, 0.04 in Q4 2024, and 0.04 in Q4 2023.